Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

Masakatsu Nakamura; Toshimi Otsuka; Ranji Hayashi; Tomoe Horita; Masafumi Ota; Naoko Sakurai; Hikaru Takano; Tasuku Hayashi; Motona Kumagai; Sohsuke Yamada; Tomiyasu Arisawa

doi:10.2169/internalmedicine.4699-20

CASE REPORTS

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

Masakatsu Nakamura, Toshimi Otsuka, Ranji Hayashi, Tomoe Horita, Masafumi Ota, Naoko Sakurai, Hikaru Takano, Tasuku Hayashi, Motona Kumagai, Sohsuke Yamada, Tomiyasu Arisawa

Author information

Masakatsu Nakamura
Department of Gastroenterology, Kanazawa Medical University, Japan
Toshimi Otsuka
Department of Gastroenterology, Kanazawa Medical University, Japan
Ranji Hayashi
Department of Gastroenterology, Kanazawa Medical University, Japan
Tomoe Horita
Department of Gastroenterology, Kanazawa Medical University, Japan
Masafumi Ota
Department of Gastroenterology, Kanazawa Medical University, Japan
Naoko Sakurai
Department of Gastroenterology, Kanazawa Medical University, Japan
Hikaru Takano
Department of Gastroenterology, Kanazawa Medical University, Japan
Tasuku Hayashi
Department of Gastroenterology, Kanazawa Medical University, Japan
Motona Kumagai
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan
Sohsuke Yamada
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan
Tomiyasu Arisawa
Department of Gastroenterology, Kanazawa Medical University, Japan

Keywords: immune-related hepatitis, durvalumab, non-small cell lung cancer

JOURNAL OPEN ACCESS

2020 Volume 59 Issue 21 Pages 2711-2717

DOI https://doi.org/10.2169/internalmedicine.4699-20

Browse “Advance online publication” version

Details

Abstract

We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m²), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged.

Corresponding author

Register with J-STAGE for free!